Atlas Trials

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical trial NCT06827080 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06827080
Sponsor
Zhengguo Chen
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer, MCRPCCancer
Start date
2025-02-11
Primary completion
2026-12-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.